SinoMab Bioscience Overview
- Year Founded
-
2001
- Status
-
Public
- Employees
-
42
- Stock Symbol
-
03681
- Investments
-
1
- Share Price
-
$0.12
- (As of Friday Closing)
SinoMab Bioscience General Information
Description
SinoMab BioScience Ltd is a biopharmaceutical company focused on the research, development, manufacturing, and commercialisation of therapeutics for the treatment of immunological diseases, mainly monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential first-in-class mAb against CD22 for the treatment of rheumatoid arthritis (RA) and other immunological diseases. In addition, the company possesses other potential first-in-class drug candidates (like SM17, SN1011, SM06, SM09, etc.) some of which are already in the clinical stage, with their indications covering rheumatoid arthritis (RA), Sjogren's syndrome (SS), systemic lupus erythematosus (SLE), atopic dermatitis (AD), idiopathic pulmonary fibrosis (IPF), asthma, and other diseases.
Contact Information
Website
www.sinomab.comCorporate Office
- Units 303 and 305 to 307, Number 15 Science Park West Avenue
- Hong Kong Science Park, Pak Shek Kok
- Hong Kong
- Hong Kong
Corporate Office
- Units 303 and 305 to 307, Number 15 Science Park West Avenue
- Hong Kong Science Park, Pak Shek Kok
- Hong Kong
- Hong Kong
SinoMab Bioscience Stock Performance
As of 13-Nov-2026, SinoMab Bioscience’s stock price is $0.12. Its current market cap is $169M with 1.39B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.12 | $0.13 | $0.12 - $0.28 | $169M | 1.39B | 683K | -$0.02 |
SinoMab Bioscience Financials Summary
As of 30-Jun-2026, SinoMab Bioscience has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 173,945 | 276,056 | 192,662 | 234,016 |
| Revenue | 0 | 0 | 282 | 193 |
| EBITDA | (25,783) | (10,544) | (21,194) | (29,207) |
| Net Income | (26,089) | (14,599) | (25,802) | (34,363) |
| Total Assets | 100,758 | 129,791 | 103,163 | 119,599 |
| Total Debt | 39,273 | 48,379 | 66,064 | 63,596 |
SinoMab Bioscience Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
SinoMab Bioscience Patents
SinoMab Bioscience Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026148573-A1 | Anti-il-17rb antibody for preventing or treating sinusitis or related symptoms or antigen-binding fragment thereof, and pharmaceutical composition comprising same | Pending | 10-Jan-2025 | ||
| WO-2025218746-A1 | Methods of treating rheumatoid arthritis | Pending | 17-Apr-2024 | ||
| AU-2025235859-A1 | Method of identifying anti-siglec antibodies possessing cis-trans converter properties, anti-siglec antibodies and use thereof | Pending | 12-Mar-2024 | ||
| WO-2025190311-A1 | Method of identifying anti-siglec antibodies possessing cis-trans converter properties, anti-siglec antibodies and use thereof | Pending | 12-Mar-2024 | ||
| AU-2023475632-A1 | Use of anti-il-17rb antibody or antigen-binding fragment thereof or composition | Pending | 05-Dec-2023 | A61K39/395 |
SinoMab Bioscience Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
SinoMab Bioscience Investments (1)
SinoMab Bioscience’s most recent deal was a Early Stage VC with D2M Biotherapeutics for . The deal was made on 31-Jul-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| D2M Biotherapeutics | 31-Jul-2020 | Early Stage VC | Drug Delivery |
SinoMab Bioscience ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
SinoMab Bioscience FAQs
-
When was SinoMab Bioscience founded?
SinoMab Bioscience was founded in 2001.
-
Where is SinoMab Bioscience headquartered?
SinoMab Bioscience is headquartered in Hong Kong, Hong Kong.
-
What is the size of SinoMab Bioscience?
SinoMab Bioscience has 42 total employees.
-
What industry is SinoMab Bioscience in?
SinoMab Bioscience’s primary industry is Drug Delivery.
-
Is SinoMab Bioscience a private or public company?
SinoMab Bioscience is a Public company.
-
What is SinoMab Bioscience’s stock symbol?
The ticker symbol for SinoMab Bioscience is 03681.
-
What is the current stock price of SinoMab Bioscience?
As of 13-Nov-2026 the stock price of SinoMab Bioscience is $0.12.
-
What is the current market cap of SinoMab Bioscience?
The current market capitalization of SinoMab Bioscience is $169M.
-
What is SinoMab Bioscience’s annual earnings per share (EPS)?
SinoMab Bioscience’s EPS for 12 months was -$0.02.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
